Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 14/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347931 | 0.86 | ALDH1A1 (0.46) | SCD | |
| SCHEMBL1911632 | 0.84 | SCD (0.40) | SCDSCN9ASCN10A | |
| SCHEMBL243883 | 0.82 | SCD (0.53) | SCDPIK3CDPIK3CAPIK3CB | |
| SCHEMBL347605 | 0.82 | SCD (0.51) | SCDPIK3CDPIK3CAPIK3CB | |
| SCHEMBL241830 | 0.80 | SCD (0.51) | SCDPIK3CDPIK3CAPIK3CB | |
| SCHEMBL348625 | 0.79 | SCD (0.50) | SCDPIK3CDPIK3CAPIK3CB | |
| SCHEMBL242156 | 0.79 | SCD (0.57) | SCDPIK3CDPIK3CAPIK3CB | |
| SCHEMBL243073 | 0.79 | SCD (0.59) | SCDPIK3CDPIK3CAPIK3CB | |
| SCHEMBL244565 | 0.78 | SCD (0.59) | SCDPIK3CDPIK3CAPIK3CB | |
| SCHEMBL242625 | 0.78 | SCD (0.59) | SCDPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245029-B1 | HETEROCYCLIC INHIBITORS OF STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| EP-2245029-B1 | HETEROCYCLIC INHIBITORS OF STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| CN-102007123-B | Heterocyclic inhibitors of stearoyl-CoA desaturase | NOVARTIS AG | 2014-04-30 | — | — | CN | disclosed |
| US-8318949-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014906-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885PIK3CD 2361/4885PIK3CA 2130/4885 |
| US-20090264444-A1 | Organic compounds | SCD, SCD5, FADS2 | SCD 1/4885PIK3CD 2361/4885PIK3CA 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.